Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-14 11:50:52 - browse：17853

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： States should stop sabotaging methadone treatment reform

hotspot

WSS

Devoted Health’s losses in Medicare Advantage persist

Abortion pill case raises question: who can sue the FDA?

Covid vaccine financial winners and losers, from Pfizer to Novavax

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

hotspot

Wikipedia

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

Merck drug for rare lung condition set for approval in U.S.

Medical records are filled with copy

There's no autism epidemic. It's an autism diagnosis epidemic

Anesthesiologist group: stop taking Ozempic before surgery

Vertex Pharmaceuticals may move headquarters in Boston

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Primary care physicians play key roles in Alzheimer's management

At least 13 dead in Texas as scorching temps continue

Supreme Court mifepristone arguments center on docs' right to sue

explore

The Biogen Aduhelm mess could happen again

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Global cancer cases to surge 77% by 2050, WHO report says

The Biogen Aduhelm mess could happen again

The CDC's new social media misinformation war

focus

hotspot

focus

entertainment